Business Wire

Innovaderm Research Rebrands as Indero, a Dual-Focus CRO

Share

Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity reinforces the company’s dual focus on rheumatology and dermatology and recognizes the close synergy between these fields.

Innovaderm has over 25 years of clinical research experience within dermatology, and recognizes that many inflammatory and autoimmune conditions manifest across both the skin and the musculoskeletal system. Rheumatology and dermatology therefore often overlap in diagnosing and managing diseases where the immune system plays a central role, and Indero will harness its expertise to deliver comprehensive, patient-focused solutions for these markets. The company’s full-service approach can support both early and late-phase trials across both specialties.

Dr Robert Bissonnette, Founder and Executive Chairman, commented: “As Innovaderm, we have served the dermatology clinical research community for 25 years, building a reputation for quality and excellence. As we move forward as Indero, we will continue to provide the expertise in dermatology that our clients have come to expect from us, while further strengthening our focus on rheumatology and expanding our support within this field. We are excited about the future and supporting the development of new therapies in these two areas of research, ultimately helping to improve patients' health and quality of life.”

Jeff Smith, CEO of Indero, added: “Our dual-focus, interdisciplinary approach allows us to support clinical studies for a wide range of rheumatology and dermatology conditions. The immune-mediated nature of both disease areas means that we are perfectly positioned to support clinical research across these specialties. Our network of investigators and research sites – combined with extensive in-house experience – means that we can support sponsors with the unique requirements of trials in these fields, from difficult-to-find patient populations to complex endpoints. As Indero, we are ‘all in’ with our commitment to providing sponsors with the rigorous scientific foundation and tailored expertise that their studies need.”

Visit www.inderocro.com to explore Indero’s services and expertise.

About Indero

Indero is a dual-focus CRO for dermatology and rheumatology, with over 25 years of experience in clinical research and trial delivery. Our full-service approach – which includes everything from protocol design and patient recruitment to trial monitoring and biometrics – provides biotech and pharmaceutical sponsors with the rigorous scientific foundation and tailored expertise their studies need to reach the finish line efficiently and effectively. With capabilities in the U.S., Canada, Europe, LATAM, and APAC; vast, continuously growing relationships with investigators and patients; and a dedicated research clinic through which we design and execute our own studies, Indero is the ideal partner for clinical needs at global scale.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250307129954/en/

Contacts

For more information:
Valerie Coveney
Communications Specialist
Indero
vcoveney@inderocro.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Beating The Risks of Expanding Into Emerging Market IT Channels17.3.2025 09:00:00 EET | Press release

For IT vendors, emerging markets are risky. Local regulations, cultural differences, local currencies, channel liquidity, and settling disputes complicate such plans. Fortunately, a new generation of channel finance solutions is smoothing the journey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250314300371/en/ Boris Todorov, Executive Vice President of WeFi's Client Solutions Group The emerging market growth trend Emerging markets are becoming the engines powering global and regional trade, growing at an annual rate of 4.2% (IMF), versus 1.7% in mature economies, and contributing two-thirds to global growth. India's heavy investments in its technology sector, China's focus on modern healthcare, Brazil's ambitions for green energy, and the rise of mobility among African countries—digital technology enables strong growth in emerging markets. Technology vendors are changing how they tap into those markets through supporting

Bureau Veritas Strengthens Its Leading Position in the Chilean Copper Market Through the Acquisition of GeoAssay17.3.2025 08:30:00 EET | Press release

Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces the acquisition of GeoAssay. This transaction cements Bureau Veritas’ position as the Metals & Minerals market leader in Chile, the world’s largest copper producer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250316180459/en/ Hinda Gharbi, Chief Executive Officer at Bureau Veritas Bureau Veritas’ Metals & Minerals operations aim to support our clients throughout the entire mining cycle, from mine to port. This is achieved by accurately determining the physical, chemical and geochemical properties of materials through our extensive network of laboratories. With a global presence in major ports around the world and with global mining and refining locations, Bureau Veritas’ footprint is expanding in this resource-rich region. GeoAssay specializes in copper, an essential mineral for energy transition at scale. Capabilities incl

H2SITE and SNAM Collaborate on an Innovative Hydrogen and Natural Gas Separation Project Promoted by ARERA17.3.2025 08:00:00 EET | Press release

H2SITE, a leading company in hydrogen separation technology and hydrogen transportation solutions, has announced its collaboration with SNAM, one of Europe’s key energy infrastructure operators, to develop an innovative project focused on the separation of hydrogen and natural gas mixtures. As part of this initiative, H2SITE has designed a Pd-alloy membrane separator, capable of extracting hydrogen from 2% to 10% concentrations. Once built, this unit will represent the largest installation of its kind, capable of separating hydrogen at low concentrations while achieving high recovery rates. The Pd-alloy membrane separator allows the recovered hydrogen to be used directly in fuel cells, hydrogen-to-power solutions such as gas turbines and engines, and high-temperature ovens. At the same time, it minimizes the hydrogen content in the remaining natural gas, preventing unwanted alterations in its composition. This is particularly important for industrial consumers whose processes cannot to

Murata Announces Production of "CELLNETTA" – the World's First Metal Cell Fractionation Filter17.3.2025 08:00:00 EET | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announced today that has successfully commercialized and mass produced "CELLNETTA," the world’s first*1 metal cell fractionation filter designed for the rapid and precise selection and recovery of target cells from cell suspensions*2 used in regenerative medicine and cell pharmaceutical research and development. Target applications include fractionation (selection and recovery), concentration, and filtration in research and development for regenerative medicine technologies or cellular pharmaceuticals, as well as biotechnology across agriculture, forestry, food, and energy industries. The product will be showcased at the 24th Annual Meeting of the Japanese Society for Regenerative Medicine happening March 20-22, 2025 at Pacifico Yokohama North. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312846176/en/ [Murata Manufacturing Co., Ltd.] "CELLNETTA" –the met

SES Update on Annual General Meeting Agenda14.3.2025 21:41:00 EET | Press release

SES S.A. (“SES” or the “Company”) today issued the following statements in relation to the Company’s upcoming Annual General Meeting (“AGM”), taking place on 3 April 2025: Proposed Additions to SES’s Board of Directors The Company is pleased to propose the addition of two new members, Ellen Lord and John Shaw, to its Board of Directors. Ellen Lord is the former Under Secretary of Defense for Acquisition and Sustainment of the United States Department of Defense and has board experience with listed and non-listed companies, including Voyager Space Holdings Inc., National Defense Industrial Association and Defense Technology Initiative. John Shaw is a former Deputy Commander of the U.S. Space Force and first Commander of the USSF Space Operations Command and Combined Forces Space Component Command. The Company believes that adding the unique and valuable experience and skillsets of Ellen and John to its Board, both of whom bring direct experience in U.S. Department of Defense and U.S. Sp

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye